FAIL-T (AFP, AST, tumor sIze, ALT, and Tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE
Apichat Kaewdech(Prince of Songkla University), Teerha Piratvisuth(Prince of Songkla University), Pimsiri Sripongpun(Prince of Songkla University), Sawangpong Jandee(Prince of Songkla University), Panu Wetwittayakhlang(Prince of Songkla University), Suraphon Assawasuwannakit(Prince of Songkla University), Naichaya Chamroonkul(Prince of Songkla University)
Cited by 20
Related Papers
Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals
|The Journal of Clinical Endocrinology & Metabolism|2022|306
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
|Hepatology International|2020|295
Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies
|Clinical Gastroenterology and Hepatology|2023|123
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
|Journal of Hepatology|2022|121
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)
|Clinical Gastroenterology and Hepatology|2020|103